The Accelerating Medicines Partnership® program in Heart Failure AMP® HF, launched on September 29, 2022, seeks to address a critical unmet need in cardiovascular health by better understanding the phenotypic diversity of heart failure with preserved ejection fraction (HFpEF) that will allow for the identification of novel proteins or genes with the potential to serve as therapeutic targets.

“Up until now, developing effective therapeutic strategies to identify and treat the serious heart condition known as HFpEF has eluded us,” said Julie Gerberding, President and CEO, FNIH. “Through AMP HF, we are harnessing the valuable perspectives and expertise that collaborations bring to biomedical research, paving the way to a more hopeful future for people who have HFpEF.”

Bringing together resources from the NIH’s National Heart, Lung, and Blood Institute (NHLBI), U.S. Food and Drug Administration (FDA), and seven industry and non-profit partners, the AMP HF launched with combined commitments totaling $37 million. The AMP HF inauguration preceded the Heart Failure Society of America’s Annual Meeting at National Harbor, Maryland, with representation from 17 stakeholders from industry, academia, government, and non-profit organizations.

At the inauguration, the NHLBI’s HeartShare program hosted a workshop highlighting the progress of six clinical centers in its program. The AMP HF builds on the infrastructure created by HeartShare whose goals closely align with the AMP HF project: deconstruction of HFpEF syndrome leading to the discovery of potential therapeutic targets. Since the AMP HF launch, the HeartShare website has been rebranded bringing together all resources and knowledge under a single, unified portal. In February 2023, the AMP HF project released its first RFP for the addition of a seventh clinical center to perform endomyocardial biopsies and tissue molecular profiling.

To learn more about the AMP HF study design, please visit this article by Nature Reviews Drug Discovery.